COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?
- PMID: 32202240
- DOI: 10.55563/clinexprheumatol/xcdary
COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?
Abstract
A severe outbreak of coronavirus disease 2019 (COVID-19) emerged in China in December 2019, and spread so rapidly that more than 200,000 cases have so far been reported worldwide; on January 30, 2020, the WHO declared it the sixth public health emergency of international concern. The two previously reported coronavirus epidemics (severe acute respiratory syndrome [SARS] and Middle East respiratory syndrome [MERS]) share similar pathogenetic, epidemiological and clinical features as COVID-19. As little is currently known about SARS-CoV-2, it is likely that lessons learned from these major epidemics can be applied to the new pandemic, including the use of novel immunosuppressive drugs.
Comment in
-
COVID-19: the new challenge for rheumatologists.Clin Exp Rheumatol. 2020 Mar-Apr;38(2):175-180. doi: 10.55563/clinexprheumatol/r3k9l6. Epub 2020 Mar 24. Clin Exp Rheumatol. 2020. PMID: 32207680 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous